David Hutton

The announcement marks the second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation.

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology.

German researchers found that their study results suggest that the effect of glaucoma on the elapsed time depends on disease progression. This uncertainty during everyday navigation tasks may adversely affect patients’ quality of life.

Prevent Blindness is offering free resources to help educate the public and allied healthcare professionals on the many types of inflammatory eye diseases, and steps that should be taken to prevent vision loss.

Researchers at the Karolinska Institute continue to investigate whether gene therapy can improve vision in people with Bothnia dystrophy, a form of hereditary blindness, prevalent in the region Västerbotten in Sweden.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

According to research conducted by investigators at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, patients with a rare inherited disease affecting their sight experienced quick vision improvements that sustained for the full year-long study.

In a presentation at the Retina Society meeting in Lisbon, Portugal, Ivana Kim, MD, explained that AU-011 (Bel-Sar) demonstrated 80% tumor control rate, 90% visual acuity preservation, and a favorable safety profile.

Jennifer Lim, MD, FARVO, FASRS, discusses her presentation on differential artery-vein analysis and how it improves OCTA performance for AI classification of diabetic retinopathy at the annual Retina Society meeting being held this year in Lisbon, Portugal.

Theodore Leng, MD, MS, sat down with David Hutton of Ophthalmology Times to discuss his presentation on Progression of Newly Diagnosed Geographic Atrophy: An Observational, Retrospective US-based Cohort Study at the annual Retina Society meeting being held this year in Lisbon, Portugal

According to the organization, the map and report provide public, professionals and decisionmakers with data on children’s vision issues at the county and state level.

The companies’ eye care line will feature refreshed design and improved packaging for Ocucyn Eyelid and Eyelash Cleanser. The full line will be introduced at the American Academy of Ophthalmology's annual meeting in Chicago.

Prem Subramanian, MD, PhD, a professor of ophthalmology at the Sue Anschutz-Rodgers Eye Center, will use high-tech ocular equipment to monitor the four-member Polaris Dawn crew to investigate why eyes change in space.

Researchers from NYU Langone published a study reporting on the eye's functioning, without sight but offering hope for the future.

Lynn Hassman, MD, PhD, has received the Philip and Elaine Ellis New Investigator in Ophthalmology Research Award, and will focus on seeking treatment options for uveitis patients.

Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.

APP13007, according to the company, is the first product developed using Formosa’s proprietary APNT nanoparticle formulation platform.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in 4Q calendar year 2024. Topline results currently are expected in late 2025

In the case study, a 63-year-old patient presented with severe acute pain in the right eye, which was diagnosed as a pupillary block leading to acute angle closure glaucoma.

BI 771716, with technology licensed from CDR-Life, is a highly specific antibody fragment, possibly enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.

Investigators at the Dean McGee Eye Institute reviewed the accuracy of the tools in measuring 5 vision assessment parameters, including distance visual acuity, near visual acuity, color vision testing, contrast sensitivity, and pupillary distance.

Prevent Blindness is planning a series of events and program partnerships leading up to World Sight Day on Oct. 10, 2024.

A team of researchers at the Center for Regenerative Therapies Dresden of Dresden University of Technology is working to develop a method to replace or regenerate damaged photoreceptor cells in the human retina.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

A team of researchers from Johns Hopkins Medicine and the University of Wisconsin-Madison conducted a study on the application of autonomous artificial intelligence and testing for diabetic eye disease.

The American Academy of Ophthalmology indicates that consumers who may see the eye color-changing drops advertised and used on TikTok or elsewhere online should be advised that they are not FDA approved.

The day will be held on October 10. It is coordinated by the International Agency for the Prevention of Blindness under the “Love Your Eyes” campaign banner, and is putting children at the center of the campaign.

Australian researchers have found that clinical registries may be an untapped font of information for artificial intelligence.

The product candidate is a modifier gene therapy for broad retinitis pigmentosa indication.